Zacks Investment Research downgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a sell rating in a research report report published on Monday.
According to Zacks, “Regeneron’s Eylea continues to perform well. Dupixent launch in the United States for moderate-to-severe atopic dermatitis is progressing well. Moreover, the company is also looking to expand Dupixent’s label in uncontrolled asthma. The approval of new drugs like Kevzara and Dupixent provides a significant boost. However, sales of Praluent have failed to impress. With Eylea accounting for the majority of revenues at Regeneron, Regeneron relies heavily on the drug for growth. In the United States., the company is witnessing increased competitor discounts and rebates. Sub-par performance of the product will hurt the stock as Eylea is Regeneron’s key growth driver. Moreover, Eylea combination studies with nesvacumab disappointed in phase II and hence the study will not be advanced into phase III. Shares have underperformed the industry in the last twelve months. Estimates have increased ahead of Q4 results.”
REGN has been the subject of several other research reports. JPMorgan Chase & Co. boosted their target price on Regeneron Pharmaceuticals from $455.00 to $457.00 and gave the stock a neutral rating in a research note on Wednesday, January 24th. Evercore ISI decreased their target price on Regeneron Pharmaceuticals from $605.00 to $445.00 and set an outperform rating for the company in a research note on Thursday, November 16th. Barclays cut Regeneron Pharmaceuticals from an equal weight rating to an underweight rating and decreased their target price for the stock from $450.00 to $395.00 in a research note on Friday, October 20th. BidaskClub upgraded Regeneron Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, January 26th. Finally, Citigroup restated a neutral rating and set a $388.00 target price (up previously from $380.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, January 9th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $465.38.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, topping the consensus estimate of $4.52 by $0.71. The firm had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm’s revenue was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.04 earnings per share. analysts forecast that Regeneron Pharmaceuticals will post 13.55 EPS for the current year.
Large investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC increased its holdings in shares of Regeneron Pharmaceuticals by 495.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 307 shares during the period. Advisory Services Network LLC increased its holdings in shares of Regeneron Pharmaceuticals by 147.0% in the fourth quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 266 shares during the period. Vident Investment Advisory LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $200,000. Virtu KCG Holdings LLC acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $206,000. Finally, AE Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $206,000. 65.69% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Regeneron Pharmaceuticals (REGN) Rating Lowered to Sell at Zacks Investment Research” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://sportsperspectives.com/2018/02/09/regeneron-pharmaceuticals-regn-rating-lowered-to-sell-at-zacks-investment-research.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.